{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PRAME+Positive",
    "query": {
      "condition": "PRAME Positive"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T21:31:49.748Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05973487",
      "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non-small Cell Carcinoma",
        "Melanoma",
        "Ovarian Cancer",
        "Anogenital Cancers",
        "HPV - Anogenital Human Papilloma Virus Infection",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Carcinoma",
        "HPV-Related Squamous Cell Carcinoma",
        "HPV-Related Malignancy",
        "HPV-Related Adenocarcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Adenosquamous Carcinoma",
        "HPV-Associated Vaginal Adenocarcinoma",
        "HPV-Related Endocervical Adenocarcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Verrucous Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma",
        "HPV Positive Rectal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TSC-204-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-05-06",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05973487"
    },
    {
      "nct_id": "NCT01159964",
      "title": "Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Immunotherapeutic GSK2302032A, different formulations",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-07-20",
      "completion_date": "2014-09-10",
      "has_results": false,
      "last_update_posted_date": "2018-06-18",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 7,
      "location_summary": "Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01159964"
    },
    {
      "nct_id": "NCT03318900",
      "title": "T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COL6A3 Positive",
        "HLA-A*0201 Positive Cells Present",
        "PRAME Positive",
        "Recurrent Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD8-Positive T-Lymphocyte",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2018-09-04",
      "completion_date": "2023-12-20",
      "has_results": true,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03318900"
    },
    {
      "nct_id": "NCT07258446",
      "title": "PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Clinical Stage 0 Cutaneous Melanoma AJCC v8",
        "Clinical Stage I Cutaneous Melanoma AJCC v8",
        "Clinical Stage II Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Immunohistochemistry Staining Method",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Mohs Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-10-24",
      "completion_date": "2033-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07258446"
    },
    {
      "nct_id": "NCT05812027",
      "title": "A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non Small Cell Lung Cancer",
        "HPV16 Related Cancers",
        "Sarcoma",
        "Uveal Melanoma",
        "NUT Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tumor and HLA Profiling",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1150,
      "start_date": "2023-06-26",
      "completion_date": "2027-01-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812027"
    },
    {
      "nct_id": "NCT04262466",
      "title": "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Select Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Brenetafusp",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and monoclonal antibodies and chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and tebentafusp",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Brenetafusp and kinase inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2020-02-25",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04262466"
    },
    {
      "nct_id": "NCT01853878",
      "title": "A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2013-06-12",
      "completion_date": "2016-08-24",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-07-21T21:31:49.748Z",
      "location_count": 8,
      "location_summary": "Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853878"
    }
  ]
}